Kinetic and affinity limits on antibodies produced during immune responses.
about
Ontogeny of recognition specificity and functionality for the broadly neutralizing anti-HIV antibody 4E10Cholesterol loading and ultrastable protein interactions determine the level of tumor marker required for optimal isolation of cancer cellsElectrophilic affibodies forming covalent bonds to protein targetsAntibody promiscuity: Understanding the paradigm shift in antigen recognitionThe structural basis of repertoire shift in an immune response to phosphocholineDistinct CDR3 conformations in TCRs determine the level of cross-reactivity for diverse antigens, but not the docking orientationReconciling the Structural Attributes of Avian AntibodiesStructure-Based Reverse Vaccinology Failed in the Case of HIV Because it Disregarded Accepted Immunological TheoryAssociation rate constants of ras-effector interactions are evolutionarily conservedHigh-affinity target binding engineered via fusion of a single-domain antibody fragment with a ligand-tailored SH3 domainIn vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin.In vitro evolution of a T cell receptor with high affinity for peptide/MHC.Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity.In vitro affinity maturation of a natural human antibody overcomes a barrier to in vivo affinity maturationPredicting the kinetics of peptide-antibody interactions using a multivariate experimental design of sequence and chemical space.Selection of recombinant, library-derived antibody fragments against p24 for human immunodeficiency virus type 1 diagnostics.Antibodies as therapeutic agents: vive la renaissance!Isolation of anti-CD22 Fv with high affinity by Fv display on human cells.Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120Back to the future: recombinant polyclonal antibody therapeutics.Mammalian cell display for antibody engineeringIn vitro antibody affinity maturation targeting germline hotspotsDisplay and selection of scFv antibodies on HEK-293T cells.High-affinity lamprey VLRA and VLRB monoclonal antibodiesGeneration of a family-specific phage library of llama single chain antibody fragments that neutralize HIV-1Computational design of antibody-affinity improvement beyond in vivo maturationUsing in vitro selection to direct the covalent attachment of human immunodeficiency virus type 1 Rev protein to high-affinity RNA ligandsThe protein-protein interface evolution acts in a similar way to antibody affinity maturation.Avidity as a determinant of the protective efficacy of human antibodies to pneumococcal capsular polysaccharidesFundamental aspects of protein-protein association kineticsMultidimensional analysis of the frequencies and rates of cytokine secretion from single cells by quantitative microengraving.Association and dissociation kinetics of anti-hen egg lysozyme monoclonal antibodies HyHEL-5 and HyHEL-10Kinetics of association of anti-lysozyme monoclonal antibody D44.1 and hen-egg lysozyme.Requirements for empirical immunogenicity trials, rather than structure-based design, for developing an effective HIV vaccine.Femtomolar Fab binding affinities to a protein target by alternative CDR residue co-optimization strategies without phage or cell surface display.Exploiting cross-reactivity to neutralize two different scorpion venoms with one single chain antibody fragmentComparative analyses of immunoglobulin genes: surprises and portents.Profiling antibody responses by multiparametric analysis of primary B cells.The influence of antibody fragment format on phage display based affinity maturation of IgG.Llama nanoantibodies with therapeutic potential against human norovirus diarrhea.
P2860
Q21089590-BAE860DA-1FB9-41DE-80F6-BE1856E7BCEEQ24594878-DAEFF8C4-311F-44D6-891B-6B4E4ED749B2Q24651974-A5EED8EB-B82B-4430-A8E8-917D28EB40B8Q26801316-8B42A05A-C299-4B1C-A325-5DB4345BC241Q27624954-831D6226-9E23-4FA7-91D7-A4ACD83AF2CFQ27652612-6DA69BD2-AB09-441A-8588-5EA574559428Q27683425-123DEEF8-D350-43E1-8CB9-98A987D0E79DQ28071559-6126DD11-E74D-4B2F-9674-1BF4B03B6638Q28474223-087EC008-D8A5-4106-9661-EF60847C7EF8Q28480982-C033BCD1-E289-40A7-8767-89746B5E613CQ30769483-564F1677-E34F-4C98-A98D-6B13761BD7FCQ30861962-6D5E30A0-8299-4DF2-BE81-546533D3A244Q30923970-9D06DA80-D924-4608-9111-43DE4FDAF9F1Q31149925-D5BDE29B-9010-4302-98CB-5BCB20F6B1D6Q31949891-E2CF30C2-A813-40FC-869C-DDD60D8B1ADEQ32026627-0556FC2F-183D-4C1E-998A-5F8703797FC7Q33193524-8E6D833A-789A-48EC-84A7-CE8A929FCA2DQ33246226-AA3E5DBC-4C8B-497C-89FF-B4BD6D9246EBQ33374701-4172CDDA-8708-4BDC-BD45-E322CA78CA1EQ33412776-3D48D81B-F2C1-4211-8626-B8A5FC7E12FDQ33413791-2F1D3975-134C-4E03-BC6B-3384A2D781F1Q33413796-D1EA65F1-8EC9-4B85-9500-5E624F44FD50Q33474388-823F7A5F-5198-4187-BDFF-243CF4BDE4A4Q33485795-6D353FFE-8DAE-4B9E-BD4A-DC0F527F3430Q33558279-C4641BC6-5D9E-43DB-A775-F7FC649F9FE7Q33576857-5AC74F35-2B08-4072-82C1-AAA6267B2D29Q33657353-C2E4274F-857E-4105-9134-32EC8D53A161Q33662167-851B083C-A332-4296-B4D0-A0BAA2E9199EQ33867137-F5AF4D35-D366-4AD3-B687-EFB72D004485Q33893739-0F7D696D-265C-495E-8B83-8494E0F9ED35Q34109159-062E6622-10FD-4006-AE1B-11BB390056AAQ34167645-09617AC8-2142-4DC9-BD5B-3D5821055C74Q34174497-E5FCF49B-7723-4057-B94F-4326441F5F8EQ34225659-BEF621B5-9C8D-4DB0-A07A-842FACB516E5Q34244499-F4B22676-12BD-4FC8-9790-0E0B148E8BD9Q34675779-70787A61-F96F-4FD9-A194-4508541F3F21Q34810278-967C4AF4-CA39-4A73-8E44-057F44B11572Q34878648-FEADA10E-0721-4801-8A6A-CBD91E05FBBFQ35050036-F3710375-02A3-4B8C-BD11-3D6F65F31CD7Q35744232-AFD8548A-0292-4292-80BC-8BF77838F7F1
P2860
Kinetic and affinity limits on antibodies produced during immune responses.
description
1995 nî lūn-bûn
@nan
1995 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
name
Kinetic and affinity limits on antibodies produced during immune responses.
@ast
Kinetic and affinity limits on antibodies produced during immune responses.
@en
Kinetic and affinity limits on antibodies produced during immune responses.
@nl
type
label
Kinetic and affinity limits on antibodies produced during immune responses.
@ast
Kinetic and affinity limits on antibodies produced during immune responses.
@en
Kinetic and affinity limits on antibodies produced during immune responses.
@nl
prefLabel
Kinetic and affinity limits on antibodies produced during immune responses.
@ast
Kinetic and affinity limits on antibodies produced during immune responses.
@en
Kinetic and affinity limits on antibodies produced during immune responses.
@nl
P2860
P356
P1476
Kinetic and affinity limits on antibodies produced during immune responses.
@en
P2093
P2860
P304
P356
10.1073/PNAS.92.5.1254
P407
P577
1995-02-01T00:00:00Z